Abstract
Back ground
Modified Blalock-Taussig shunt is an important initial palliation in a selected subset of patients. This randomized controlled study was conducted to evaluate and compare PTFE and homograft saphenous vein as a conduit for this purpose.
Patients and Methods
Thirty patients were prospectively randomized to receive either a Polytetrafluoroethylene (PTFE) or an antibiotic preserved homograft saphenous vein as conduit. Early results were analysed and compared.
Results
Mean graft size was 3.93 mm±0.53 and 4.2 mm±0.53 in the PTFE and vein group respectively. There were 3 hospital deaths in the vein group and none in the PTFE group. There were 2 early and no late shunt thromboses in PTFE group while 1 early and 2 late thrombosis occurred in vein group. These differences were statistically insignificant. The incidence of post-operative bleeding, peri-graft seroma and operative time was less in vein then PTFE group. Palliation on follow-up was comparable in both groups.
Conclusion
This study failed to demonstrate any benefit of homograft saphenous vein over PTFE graft in terms of thrombotic complications and mortality. There was however less bleeding and peri-graft seroma formation in the Saphenous vein (SVG) group. Further studies with greater number of patients and longer follow-up are required to demonstrate the superiority of either of these conduits.
Article PDF
Similar content being viewed by others
References
De Leval MR, McKay R, Jones M, Stark J, Macartney FJ. Modified Blalock-Taussig shunt: Use of subclavian artery orifice as flow regulator in prosthetic systemic-pulmonary artery shunts. J Thorac Cardiovasc Surg 1981;81:112–119.
Blalock A, Taussig HB. Surgical treatment of malformations of the heart in which there is pulmonary stenosis or atresia. JAMA 1945;128:189–202.
Gazzaniga AB, Elliott MP, Sperling DR, et al. Microporous expanded polytetrafluoroethylene arterial prosthesis for construction of aortopulmonary shunts: experimental and clinical results. Ann Thorac Surg 1976;21:322–327.
Ullom RL, Sade RM, Crawford FA Jr, Ross BA, Spinale F. The Blalock-Taussig shunt in infants: standard versus modified. Ann Thorac Surg 1987;44:539–543.
Bogats G, Kertesz E, Katona M, Toszegi A, Kovacs GS. Modified Blalock Taussig Shunt Using Allograft Saphenous Vein:six years’ experience. Ann Thorac Surg 1996;61:58–62.
Danilowicz D, Ishmael RG, Doyle EF, Isom OW, Colvin SB, Greco MA. Use of saphenous vein allografts for aortopulmonary artery anastomoses in neonates with complex cyanotic congenital heart disease. Pediatr Cardiol 1984;5:13–17.
Vincent JG, Lacquet LK, VD Wal HJ, Daniels O, van Oort A. A denaturated venous homograft as an alternative material for shunts and other reconstructions in congenital cardiac surgery. J Cardiovasc Surg (Torino) 1990;31:766–770.
Erez E, Bush D, Tam VK, Doublin NA, Stakes J. Outcome in infants less than 3 kilograms for placement of saphenous venous homografts as systemic-to-pulmonary arterial shunts. Cardiol Young 2008;18:386–391.
Brockbank KG, McNally RT, Walsh KA. Cryopreserved vein transplantation. J Cardiac Surg 1992;7:170–176.
Davies AH, Parums DV. Storage of long saphenous vein. J Cardiovasc Surg 1992;33:92–97.
Tice DA, Zerbino VR, Isom OW, Cunningham JN, Engelman RM. Coronary artery bypass with freeze preserved saphenous vein allografts. J Thorac Cardiovasc Surg 1976;71:378–382.
Bove EL, Kohman L, Sereika S, Byrum CJ, Kavey RE, Blackman MS, et al. The modified Blalock -Taussig shunt: analysis of adequacy and duration of palliation. Circulation 1987;76:19–23.
Laub GW, Muralidharan S, Clancy R, et al. Cryopreserved allograft veins as alternative coronary artery bypass conduits: early phase results. Ann Thorac Surg 1992;54:826–831.
Barner HB Allogenic saphenous vein for coronary bypass. J Thorac Cardiovasc Surg 1978;75:902–903.
Martin RS 3rd, Edwards WH, Mulherin JL Jr, Edwards WH Jr, Jenkins JM, Hoff SJ. Cryopreserved saphenous vein allografts for below-knee lower extremity revascularization. Ann Surg 1994;219:664–670.
Schwartz SI, Kutner FR, Neistadt A, Barner H, Resnicoff S, Vaughan J. Antigenicity of homografted vein. Surgery 1967;61:471–477
LeBlanc J, Albus R, Williams WG, Moes CA, Wilson G, Freedom RM, et al. Serous fluid leakage: a complication following the modified Blalock-Taussig shunt. J Thorac Cardiovasc Surg 1984;88:259–262.
Joshi K, Chowdhury UK. The modified Blalock-Taussig shunt. A retrospective study. In: MCh research papers, All India Institute of Medical Sciences, January 2006
Barner HB. Allogenic saphenous vein for coronary bypass. J Thorac Cardiovasc Surg 1978;75:902–903.
Ilbawi MN, Grieco J, DeLeon SY, et al. Modified Blalock-Taussig shunt in newborn infants. J Thorac Cardiovasc Surg 1984;88:770–775.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bishnoi, A.K., Talwar, S., Choudhary, S.K. et al. Homograft saphenous vein versus polytetrafluoroethylene graft for modified Blalock -Taussig shunt. Indian J Thorac Cardiovasc Surg 24, 227–232 (2008). https://doi.org/10.1007/s12055-008-0051-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12055-008-0051-z